ScreenerHero

QNCXQuince Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · quincetx.com
33.93USD-1.85%Mkt Cap: 34.51M $P/E: —

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap34.51M $
Enterprise Value60.49M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-83.98M $
Revenue/Share—
Last Price33.93 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees38
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.86
PEG—
EV/EBITDA-1.00
EV/Revenue—
P/S—
P/B1.41
EPS (TTM)-199.31
EPS (Forward)-4.68
52W Range
15.102% of range910.00
52W High910.00 USD
52W Low15.10 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE235.14%
ROA-89.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-41.42M $
CapEx (TTM)352.00K $
FCF Margin—
FCF Yield-107.33%
Net Debt-115.98M $
Net Debt/EBITDA1.91
Balance Sheet
Debt/Equity-0.52
Current Ratio14.52
Quick Ratio13.64
Book Value/Sh22.73 USD
Cash/Share114.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 30, 2026
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)77.20 USD
Upside (mean)+127.5%
Target Range68.00 USD – 98.00 USD
$68.00+127.5% to mean$98.00
# Analysts5
Ownership
Shares Out.1.02M
Float929.16K
Insiders0.30%
Institutions34.90%
Short Interest
Short Ratio1.4d
Short % Float5.58%
Short % Out.5.57%
Shares Short56.63K
Short (prev mo.)112.79K
Technical
SMA 5022.17 (+53.0%)
SMA 200191.93 (-82.3%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)35.91K
Avg Vol (10d)31.78K
Technical Indicators
RSI (14)78.6
MACD3.8113
MACD Signal3.2175
MACD Hist.+0.5938
BB Upper39.26 USD
BB Middle27.32 USD
BB Lower15.39 USD
BB Width87.38%
ATR (14)2.229 USD
Vol Ratio (20d)0.26x